Introduction
The cholera disease is am ajor source of suffering around the world. This diarrheal disease is caused by the Vibrio cholerae bacteria,b ut it is the cholera toxin (CT) it produces that is the actual pathogenic species. The toxin attaches itselft ot he intestinal cell wall where it is subsequently internalized and the A-subunit of this AB 5 toxin [1] subsequently initiates the disease by raising the cellular cyclic adenosine monophosphate (cAMP) concentration followed by fluid efflux into the intestines. [2] The initial attachment of the toxin to the intestinal cell surfacei s caused by the five B-subunits (CTB 5 )t hat surround the A-subunit. While as ingle Bbinding site already binds with nanomolar affinities to aG M1-oligosaccharide (GM1os), simultaneous bindingo fm ore than one B-subunit of the toxin can greatly enhancei ts affinity (Figure1). Blockingt he initial attachment of the toxin to the cell surfaceh as the potentialt ob lock the disease. Considering the fact that the toxin itselft akes advantage of multivalency [3, 4] in its binding to the cell surface, it was clear that, in order to interferee ffectively,amultivalent ligand system would have to be designed.
Several evaluated multivalents ystemsh ave been designed based on dendrimers, [5, 6] polymers [7, 8] peptides, [9] and also pentavalents caffolds [10] [11] [12] andh ave clearly shown the promise of the multivalency approach. [13] [14] [15] [16] In one such approachw ea ttachedt he GM1os to dendritic scaffolds of varying valencies. Especially effectivew eret he tetra-and octavalent systems, which were able to inhibit CTB 5 at subnanomolar concentrations and with potency enhancements orders of magnitude larger than the corresponding monovalentligand. [17] Subsequents tudies with the close relative of the cholera toxin, the heat labile enterotoxin of E. coli (LT), showed that the multivalent ligands, when mixed with the toxin, would lead to aggregates involving many toxin molecules. [18] This was shownb ya nalytical ultracentrifuge experiments as well as by atomic force microscopy.T he observed aggregation was attributed to the mismatch in valency between the multivalent ligand (four or eight) and the multisubunit toxin (five). In fact, it was considered ap ossibilityt hat the enormousp otency enhancements observed in the inhibition assay with the cholera toxin could be due to the mismatch andt he subsequent aggregation that the multivalent ligands initiated. On the other hand, there were reports in the literature, which described symmetrical pentavalent CT or LT ligands that were shown to be potent toxin inhibitors that clearly formed a1 :1 complex with the toxin, as judgedb yd ynamic light scattering (DLS) exThe five B-subunits (CTB 5 )o ft he Vibrio cholerae (cholera)t oxin can bind to the intestinal cell surfaces ot he entire AB 5 toxin can enter the cell. Simultaneous binding can occur on more than one of the monosialotetrahexosylganglioside (GM1) units presento nt he cell surface. Such simultaneous binding arising from the toxin'sm ultivalency is believed to enhancei ts affinity. Thus, blocking the initial attachment of the toxin to the cell surfaceu sing inhibitors with GM1 subunits hast he potentialt o stop the disease. Previously we showedt hat tetravalent GM1 molecules were sub-nanomolar inhibitors of CTB 5 .I nt his study, we synthesized ap entavalent version and compared the binding and potency of penta-and tetravalent cholera toxin inhibitors, based on the same scaffold, for the first time. The pentavalentg eometry did not yield major benefits over the tetravalent species, but it was still as trongi nhibitor,a nd no major steric clashes occurredw hen binding the toxin. Thus, systems which can adopt more geometries, such as those described here, can be equally potent, and this may possibly be due to their ability to form higher-order structures or simply due to more statistical options forbinding.
periments. [10] Based on the 1:1d esign, severalp entavalent CT inhibitors were reported, and it was suggested that this design was beneficial to the inhibition. [11, 12] This also included am odified version of the cholera toxin that can no longer bind GM1 and was outfitted with 5GM1os ligands. [19] The relatedS higalike toxin has also seen ap otent inhibitor with five arms for each subunit. [20] Potent inhibition was seen, although the binding mode, involving two toxins, was not as expected, as the two ligandsp er arm engaged two separate toxins rather than two binding sites per toxin subunit. However, so far,n oe xperiments were undertaken that compared am atching pentavalent CT inhibitor with inhibitors of nonmatching valencies based on closely relateds caffolds. Therefore, it remains very much unclear which of the two approaches-1:1 design or mismatch-aggregation-is the best. We now address this question and report on the synthesis and evaluation in the same assay of tetra-and pentavalent GM1-based ligand systemsf or CT inhibition.
Results and Discussion

Synthesis
The synthesis started with the preparation of the scaffold for the tetravalent inhibitor 5,w hich was subsequently used for the preparation of the scaffold for the pentavalent inhibitor 8 (Scheme 1). The overall design of the tetravalent inhibitor was kept close to the previousv ersion (inhibitor 11) [17] although there were differences in the spacer arms due to the availability and use of ad ifferent GM1os building block, that is, 6 in this case. The length of the spacera rm was almostt he same as before,w ith the present one just measuring two atoms longer.F urthermore, the previous partly hydrophobic and partly hydrophilic spacera rm was now replaced by one consisting almost entirely of hydrophilic ethylene glycol units.
The synthesis started with the elongation of the four arms of 1 as previously described. [5] The spacer 2 [21] was coupled to the dendritic scaffold 1 by the action of benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate( BOP) and N,N-diisopropylethylamine (DIPEA), which resulted in 3 in 50 %y ield. After that, trifluoroacetic acid (TFA) was used to remove the Boc protectingg roup from the amino groups of 3, and ac ouplingr eaction between 3 and 4 [22] using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate( HATU) and DIPEA afforded the tetrameric full length scaffold 5 in 60 %y ield over two steps. Microwave-assisted copper(I)-catalyzeda zide-alkyne cycloaddition (CuAAC) was subsequently used to conjugate the GM1os derivative 6 to the scaffold 5,w hich efficiently yieldedt he tetravalent GM1 derivative 7.T he latter was purified by preparative high-performancel iquid chromatography (HPLC).
The tetravalent scaffold 5 formed the starting point for the synthesis of the pentavalent version (Scheme1,s teps e-g). To this end, the methyl ester of 5 was saponified quantitatively by base. The resulting carboxylic acid was coupled to the commerciallya vailables pacer 9 using BOP and DIPEA, which successfully gave 8 as the pentavalent scaffold in 51 %y ield over two steps. Subsequently,amicrowave-assisted CuAAC conjugation reaction was employed on 8 and 6 leadingt ot he formationo ft he pentavalent GM1 derivative 10,w hichw as purified by preparative HPLC.
Inhibition
The compounds weree valuated as CTB 5 inhibitors using an assay similar to an enzyme-linked immunosorbent assay (ELISA), as previously described.
[17] A9 6-well ELISA plate was coatedb yt he naturalb ovine brain GM1 ganglioside. The remaining binding sites were blockedw ith bovine serum albumin (BSA). Horseradish peroxidase (HRP)-conjugated CTB 5 was incubated with varying concentrationso ft he tested inhibitors for 2h at room temperature. After that, the remaining activity of CTB 5 was measured upon addition of the solutions to the www.chemistryopen.org wells and incubation for 30 min at room temperature to allow for binding of the remaining toxin. After incubation and washing, the amount of bound toxin was quantifiedbyusing achromogenics ubstrate for HRP.T he previously reported [17] tetravalent GM1 compound 11 was used here as ar eference in inhibitory potencye valuation. In the present assay, 11 showeda n IC 50 of 190 pm,avalue close to the previously reported one (230 pm)( Ta ble 1). The new tetravalent GM1 compound 7 exhibited av ery similari nhibitory potency, with an IC 50 of 160 pm.T his result shows that as lightly differentspacer length and considerably different spacerp olarity did not lead to significantly different inhibitory properties. The pentavalent GM1 derivative 10 exhibited an IC 50 of 260 pm,w hich is in the same range as the values found for both of the tetravalent ligands. This indicates that in our assay,t he potency of the ligand of matching valency does not essentially differ from the potencies of its nonmatching analogues.
Sedimentationv elocity analytical ultracentrifugation (SV-AUC)
In order to learn whethert he pentavalent geometry of 10 leads to ad ifferent, possibly less aggregative, bindingm ode, SV-AUC [23, 24] experiments were undertaken.F irst as ample with just CTB 5 was measured. It contained as ingle species with as edimentation coefficient of 4.4 Sc orresponding to am ass of 58 kDa for the protein pentamer.S isu et al. [18] previously used SV-AUC to test the tetrameric GM1os dendrimer 11 with LTB 5 , and it was found to strongly aggregate the protein while no discreteo ligomers were observed. In the presente xperiments, tetravalent inhibitor 7,w hich is structurally similart o11,w as added to CTB 5 at ap entamer concentrationo f5 0mm.W ith the addition of 0.2-1.0 equivalents, ad ramatic reduction in the overall signal was observed, as had previously been shown for 11 and LTB 5 ,i ndicatingr apid sedimentation of aggregating large particles (Figure 2 , see also Supporting Information). However,w ith inhibitor 7,t he emergence of ap eak at 7.2 AE 0.2 Sw as seen with ap redicted mass of approximately 110kDa, which corresponds to ad imer of CTB pentamers. With increasing amountso fi nhibitor up to 10 equivalents, the amount of the dimer species increased,a nd the emergence of some stable CTB pentamers was also observed. Excess and unbound inhibitor was observeda sapeak at 0.9 AE 0.1 Sc orresponding to amass of 8kDa.
Pentavalenti nhibitor 10 matched the number of ligand groups to the number of binding sites of CTB 5 and so it was expected that this inhibitor should form stable 1:1c omplexes. However,t he AUC results were very similart othose observed for tetravalent ligand 7.Areduction in signal indicatedl arge scale aggregation, and some dimerizationo fC TB pentamers was observed. Again, at highere quivalents of inhibitor,s ome CTB pentamers were seen but with no significant difference to the tetravalent inhibitor.
Conclusions
For the first time, penta-and tetravalent cholera toxin inhibitors based on the same scaffold were compared. The structures contained arms of sufficientl ength to simultaneously bridgea ll binding sites (see Supporting Information). Cleary, the pentavalent geometry of 10 did not yield major benefits over the tetravalent 7;i nf act, it was al ittle worse. However, it was still as trongi nhibitor,s om ajor steric clashes did not occur in the bindingo f10 to the toxin. Nevertheless one can argue that the potency per arm is significantly reduced by af actor of aboutt wo. Both 7 and 10 behaved very similarly in sedimentation velocity analytical ultracentrifugation (SV-AUC). As noted beforef or 11,a ggregationo ccurs upon toxin binding, resulting in highero rder structures, while only minor amountso fb ound pentamer (or its dimer) could be detected. The arms of the systems described here are designed in agreement with the concept that their 'effective length' [10] should match the distance they should cover.T he lengths of their extended conformations are therefore far longer. While the fifth arm is slightly shorter than the other four,i ts hould be kept in mind that it is easily capable of bridging the fifth site, and that is attached to ad ifferent site of the scaffold.
It is of interest to compareo ur results to related pentavalent systemsi nt he literature. Event houghi nhibition assay results cannotb ed irectly compared, it is af act that the same assay is used in these studies.O ne pentavalent GM1 system,b ased on ac orranulene scaffold, exhibited an IC 50 of 5nm,p resumably www.chemistryopen.org not living up to its full potential due to self-association of the scaffold. [12] Ar elated calix [5] arene-based system showedh igher potencyw ith an IC 50 of 450 pm. [11] Neither of theses ystems showedacompelling argument in favor of ap entavalent system,c onsistentw ith our results. CTB 5 ,w hose binding sites were disabled , wasr ecently used as as caffold for the display of five GM1 units. This construct showed an IC 50 of 104 pm and was shown to form a1 :1 complex with the toxin. While impressive, it is not very different from the 160 pm observed here, nor the 50 pM value for our previously reported octavalent GM1 structure. [17] It seems that ap reorganized system can indeed bind in a1 :1 fashion with CTB 5 ; [19] however,s ystems which can adopt more geometries, such as those described here, can be equally potent, and this may possibly be due to their ability to form higher-order structures or simply due to more statistical options forb inding. Bundle and Kitov provided theoretical support for the latter to explain the enhancements in the inhibition of AB 5 toxins. [25] Their model emphasized the importance of astatistical term that describes in how many ways amultivalent ligand can bind to multiple binding sites-this was called avidity entropy.T his was used to explain why an octavalent system was ab etter Shiga-like toxin inhibitor than the matched pentavalent one.
Experimental Section
General remarks:U nless stated otherwise, chemicals were obtained from commercial sources and used without further purification. Solvents were purchased from Biosolve (Valkenswaard, the Netherlands). Acid spacers 2 [13] and 4 [22] were synthesized following literature procedures. Compound 6 was purchased from Elicityl (Crolles, France). Microwave reactions were carried out in adedicated microwave oven:t he Biotage Initiator (Uppsala, Sweden). The microwave power was limited by temperature control once the desired temperature was reached. As ealed vessel of 2-5 mL was used. Analytical HPLC runs were performed on aS himadzu automated HPLC system (Kyoto, Japan) with ar eversed-phase column (Reprospher 100, C8, 5 mm, 250X4.6 mm, Dr.M aisch GmbH, Ammerbuch-Entringen, Germany), equipped with an evaporative lightscattering detector,P LELS 1000 (Polymer Laboratories, now Varian, Inc.,P alo Alto, USA) and aS himadzu SPD-10A VP UV/Vis detector operating at 220 and 254 nm. Preparative HPLC runs were performed on an Applied Biosystems workstation (Waltham, USA). Elution was performed using ag radient of 5% CH 3 CN and 0.1 %T FA in H 2 Ot o5%H 2 Oa nd 0.1 %T FA in CH 3 CN. 1 HNMR (400 MHz) and 13 CNMR (100 MHz) spectra were recorded on an Agilent 400-MR spectrometer (Santa Clara, USA). Heteronuclear single quantum coherence (HSQC) spectroscopy and total correlated spectroscopy (TOCSY) NMR (500 MHz) measurements were performed on aV ARIAN INOVA-500 (Palo Alto, USA). Electrospray ionization mass spectrometry (ESI-MS) experiments were performed on aS himadzu LCMS QP-8000. High resolution quadrupole-time-of-flight mass spectrometry (HRMS-QTOF)a nalysis was recorded using Bruker ESI-Q-TOF II (Billerica, USA). The proton numbering scheme of all compounds can be found in the Supporting Information and is used in the assignments of the signals in the NMR spectra here.
CTB 5 inhibition assay:A9 6-well plate was coated with as olution of GM1 (100 mL, 2 mgmL À1 )i np hosphate buffered saline (PBS). Unattached ganglioside was removed by washing with PBS twice, and the remaining binding sites of the surface were blocked with BSA (1 %), which was followed by washing with PBS three times. Samples of toxin-peroxidase conjugate (final concentration of 40 ng/ml CTB-HRP,S igma) and inhibitor (final concentration of 10 À6 -10 À12 m)i nP BS with BSA (0.1 %)/Tween-20 (0.05 %) were incubated at rt for 2h and were then transferred to the GM1-coated plate. After 30 min of incubation, the solution was removed and the wells were washed three times with PBS with BSA (0.1 %)/Tween-20 (0.05 %). To identify toxin binding to surface-bound GM1, the wells were treated with afreshly prepared solution of o-phenylenediamine/H 2 O 2 in citrate buffer (pH 4.5, 100 mL) for 15 min. After being quenched with H 2 SO 4 (2.5 m,5 0mL), the absorbance in each well was measured at 490 nm. Inhibition data from three experiments were averaged and fitted in GraphPad Prism 5.0 (La Jolla, USA). (See Supporting Information for examples of the fitted data.)
Analytical ultracentrifugation experiments:M ixtures of CTB 5 with various amounts of inhibitors were prepared within 1h before analysis was carried out. Samples (0.4 mL) were centrifuged in 12 mm pathlength 2-sector Al-centerpiece cells with sapphire windows in aA n60Tia nalytical rotor running in an Optima XL-I or Optima XL-A analytical ultracentrifuge (Beckman Instruments, Inc., Palo Alto, USA) at 60 krpm and at 25 8C. Changes in solute concentration were detected by 300 absorbance scans measured at 280 nm over ap eriod of 5-6 h. Analysis and fitting of the data was performed using the software SedFit v.14.3. [26] Ac ontinuous c(s) distribution model was fitted to the data, taking every 2 nd scan. The resolution was set at 200 over as edimentation coefficient range of 0.0-15.0 S. Parameters were set for the partial specific volume as 0.73654 mL g À1 ,t he buffer density of 1.04910 gmL À1 , and the buffer viscosity at 0.00141 Pa s, as calculated using SEDNTERP v.2.0 for 0.1 m PBS. The frictional coefficient, the baseline, and the raw data noise were floated in the fitting. The meniscus and bottom of the cell path were also floated after initial estimations from the raw data.
Compound 3:T oasolution of tetraamine 1 [5] (443 mg, 0.82 mmol) and spacer 2 [21] (1.7 g, 3.90 mmol) in dry dimethylformamide (DMF, 15 mL), BOP (2.56 g, 5.79 mmol) and DIPEA (1.48 g1 1.48 mmol) were added. The mixture was stirred at rt overnight and then concentrated in vacuo. The residue was purified by silica gel chromatography to afford 3 (780 mg, 50 %). 1 Ha nd 13 CNMR were consistent with ref. [5] Compound 5:C ompound 3 (780 mg, 0.33 mmol) was treated with TFAi nC H 2 Cl 2 (1:1, 20 mL) for 3h at rt, after which the volatiles were removed under reduced pressure, and the residue was dried under high vacuum. Meanwhile, compound 4 was prepared following the literature procedure. [22] The obtained amine TFAs alt of 3 and the spacer 4 (670 mg, 2.30 mmol) were dissolved in anhydrous DMF (15 mL), then HATU (875 mg, 2.30 mmol) and DIPEA (892 mg, 6.90 mmol) were added. The mixture was stirred at rt overnight and then concentrated in vacuo. The residue was purified by silica gel chromatography to afford 5 (600 mg, 60 %); [22] (dioxane/MeOH/4 n NaOH 30:9:1, 5mL). The mixture was stirred at rt until the total disappearance of the starting material. After that, the reaction was quenched by adding 1 n KHSO 4 ,a nd the mixture was concentrated in vacuo. The residue was redissolved in CH 2 Cl 2 (20 mL) and washed with 1 n KHSO 4 (10 mL), H 2 O( 10 mL), and brine (10 mL), dried on Na 2 SO 4 ,a nd concentrated in vacuo. The resulting acid was used for the next step without further purification. To as olution of this acid and amine spacer 9 (O-(2-Aminoethyl)-O'-(2-azidoethyl)heptaethylene glycol, 70 mg, 0.16 mmol, Sigma-Aldrich) in dried DMF (10 mL), BOP (60 mg, 0.13 mmol) and DIPEA (40 mg, 0.31 mmol) were added. The mixture was stirred at rt overnight. Afterwards, the reaction was stopped and concentrated. The residue was suspend into CH 2 Cl 2 (30 mL) and washed with 1 n KHSO 4 (15 mL), 1 n NaHCO 3 (15 mL), H 2 O( 15 mL), and brine (15 mL). The organic layer was collected, dried on Na 2 SO 4 ,a nd filtered. After concentration, the resulting material was purified by silica gel chromatography to afford 8 as ac olorless oil (175 mg, 0.05 mmol, 51 %o ver two steps); 
